What is The Daavlin?
Operating under the brand identity Phothera, The Daavlin specializes in the development and distribution of advanced phototherapy solutions. The company provides a comprehensive suite of devices engineered to address chronic skin conditions such as psoriasis, eczema, and vitiligo. By bridging the gap between professional clinical environments and patient-centric home treatment, the firm has established a critical niche in the dermatology market. Their commitment to user-friendly design and clinical efficacy has solidified their reputation as a reliable provider of light-based therapeutic interventions, catering to a diverse demographic of healthcare providers and individual patients seeking accessible, high-quality dermatological care.
How much funding has The Daavlin raised?
The Daavlin has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in The Daavlin
PPP
Public-Private Partnership
What's next for The Daavlin?
With the infusion of this latest capital, The Daavlin is poised to accelerate its strategic initiatives, focusing on product innovation and market expansion. The transition to the Phothera brand signifies a broader commitment to enhancing service delivery and technological integration. Future growth will likely center on scaling the distribution of home-use devices, which are increasingly in demand as the healthcare industry shifts toward decentralized, patient-managed care models. By leveraging its established clinical footprint, the company aims to capture a larger share of the global phototherapy market, ensuring that its therapeutic solutions remain at the forefront of dermatological innovation while maintaining rigorous standards for safety and patient outcomes.
See full The Daavlin company page
